Understanding mitochondrial changes in high-risk prostate cancer
Investigating mitochondrial dysfunction in high-risk prostate cancer
This study is looking at how changes in mitochondrial DNA might affect prostate cancer in African American men, who are more likely to face serious cases, with the hope of finding ways to predict and improve treatment for those at risk.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-11231990 on NIH RePORTER |
What this research studies
This research investigates the role of mitochondrial DNA alterations in prostate cancer, particularly focusing on African American men who are at higher risk for aggressive disease. The study aims to identify specific mitochondrial changes that could help in predicting which patients are more likely to develop severe forms of prostate cancer. By analyzing these genetic factors, the research seeks to improve early detection and treatment strategies tailored to individual patients. The ultimate goal is to enhance survival rates by providing better precision medicine approaches based on mitochondrial insights.
Who could benefit from this research
Good fit: Ideal candidates for this research are African American men who are at high risk for developing aggressive prostate cancer.
Not a fit: Patients with low-risk prostate cancer or those not of African American descent may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved methods for identifying and treating high-risk prostate cancer patients, potentially increasing their chances of survival.
How similar studies have performed: While there has been some research on genetic factors in prostate cancer, the focus on mitochondrial DNA alterations is relatively novel and has not been extensively tested.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Papachristodoulou, Alexandros — Rutgers Biomedical and Health Sciences
- Study coordinator: Papachristodoulou, Alexandros
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.